First Time Loading...

LogicBio Therapeutics Inc
NASDAQ:LOGC

Watchlist Manager
LogicBio Therapeutics Inc Logo
LogicBio Therapeutics Inc
NASDAQ:LOGC
Watchlist
Price: 2.07 USD
Updated: Mar 29, 2024

Intrinsic Value

LOGC price has not been updated for more than 2 months. This may indicate that the stock has been delisted.

LogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of LOGC.

Key Points:
LOGC Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of LogicBio Therapeutics Inc's business.

What risks and challenges
does LogicBio Therapeutics Inc face in the near future?

Summarize the latest earnings report
of LogicBio Therapeutics Inc.

Provide P/E
for LogicBio Therapeutics Inc and its competitors.

Financials

Balance Sheet Decomposition
LogicBio Therapeutics Inc

Current Assets 32.8m
Cash & Short-Term Investments 30.8m
Other Current Assets 2m
Non-Current Assets 5.8m
PP&E 5.2m
Other Non-Current Assets 622k
Current Liabilities 16.4m
Accounts Payable 1.1m
Accrued Liabilities 3.7m
Other Current Liabilities 11.7m
Non-Current Liabilities 6.4m
Long-Term Debt 2.6m
Other Non-Current Liabilities 3.8m
Efficiency

Earnings Waterfall
LogicBio Therapeutics Inc

Revenue
10.8m USD
Operating Expenses
-36.6m USD
Operating Income
-25.9m USD
Other Expenses
-654k USD
Net Income
-26.5m USD

Free Cash Flow Analysis
LogicBio Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

LOGC Profitability Score
Profitability Due Diligence

LogicBio Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

LogicBio Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

LOGC Solvency Score
Solvency Due Diligence

LogicBio Therapeutics Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
45/100
Solvency
Score

LogicBio Therapeutics Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LOGC Price Targets Summary
LogicBio Therapeutics Inc

There are no price targets for LOGC.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LOGC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LOGC Price
LogicBio Therapeutics Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
-70%
5Y 5Y
-79%
10Y 10Y
-82%
Annual Price Range
2.07
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return -7.02%
Standard Deviation of Annual Returns 24.28%
Max Drawdown -98%
Shares Statistics
Market Capitalization 68.2m USD
Shares Outstanding 32 962 700
Percentage of Shares Shorted 1.17%

LOGC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

LogicBio Therapeutics Inc Logo
LogicBio Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

68.2m USD

Dividend Yield

0%

Description

LogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2018-10-19. The company is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001 is developed for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. The company is developing LB-401 for the treatment of hereditary tyrosinemia type 1. The company is also developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).

Contact

MASSACHUSETTS
Lexington
65 Hayden Ave, 2Nd Floor
+16172450399.0
https://www.logicbio.com/

IPO

2018-10-19

Employees

62

Officers

Pres, CEO & Director
Mr. Frederic Chereau M.B.A.
Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Dr. Mark A. Kay M.D., Ph.D.
Chief Medical Officer
Dr. Daniel J. Gruskin M.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Leszek Lisowski M.B.A., Ph.D.
Co-Founder
Dr. Adi Barzel Ph.D.
Interim CFO, Principal Financial Officer & Principal Accounting Officer
Mr. Joshua Blacher
Show More
Global VP & Head of Technology Devel.
Dr. Matthias Hebben Ph.D.
Chief Scientific Officer
Dr. Mariana Nacht Ph.D.
Gen. Counsel & Corp. Sec.
Ms. Andrea Paul J.D.
VP & Head of HR
Ms. Grace Lochhead
Show Less

See Also

Discover More